Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER+ HER2- locally-advanced or metastatic breast cancer - PubMed
4 hours ago
- #SERD
- #Drug Resistance
- #Breast Cancer
- Resistance to next-generation SERDs in pretreated ER+ HER2- advanced breast cancer is driven by loss of luminal lineage and ERα dependence.
- Non-responding tumors upregulate ERα-independent pathways like EGFR/MAPK and Hippo/TEAD, which may be targetable.
- Giredestrant-resistant cell lines show chromatin accessibility shifts linked to transcription factors FOXA1 and FOXM1.